Key result
Terazosin treatment for 8 weeks reduced supine and upright arterial pressure and blunted cardiovascular pressor responsiveness to norepinephrine.
Why the study?
Does terazosin reduce blood pressure and cardiovascular pressor responsiveness in subjects with mild to moderate essential hypertension?
Does terazosin reduce blood pressure and cardiovascular pressor responsiveness in subjects with mild to moderate essential hypertension?
Terazosin lowers arterial pressure in essential hypertension by inhibiting alpha 1-mediated, noradrenergic-dependent vasoconstriction without altering sodium concentration or beta-adrenergic mechanisms.
Answers are grounded in this paper and cite their sources.
May lower BP in mild hypertension via alpha-1 blockade; supports mechanism but leaves open randomized outcome trials.
The effects of selective alpha 1-adrenergic blockade with terazosin on blood pressure and cardiovascular pressor responsiveness were assessed in 17 subjects with mild to moderate essential hypertension (mean age, 48 +/- 2 [SEM] years). As compared with a 2-week placebo period, 8 weeks of terazosin treatment (mean dose, 10.5 +/- 1.7 mg/day) caused a fall of supine (from 153/103 +/- 3/2 to 143/96 +/- 4/2 mm Hg; p less than 0.025) and upright (from 145/106 +/- 4/2 to 131/94 +/- 5/3 mm Hg; p less than 0.01) arterial pressure; a marked blunting of cardiovascular pressor responsiveness to norepinephrine, as judged from the pressor dose (from 73 +/- 9 to 2156 +/- 496 ng/kg/min; p less than 0.02) and from the rightward shift (p less than 0.01) of the plasma concentration-blood pressure response curve; and a slight increase in plasma norepinephrine concentration (from 37.7 +/- 3.3 to 52.2 +/- 7.8 ng/dl; p less than 0.01). Heart rate, body weight, exchangeable sodium, blood volume, and norepinephrine plasma clearance; plasma epinephrine, renin, angiotensin II, and aldosterone levels; the relationships between angiotensin II-induced increases in arterial pressure or plasma aldosterone and the concomitant increments of plasma angiotensin II; and heart rate responsiveness to isoproterenol did not change significantly after terazosin treatment. These findings suggest that the fall of arterial pressure induced by selective alpha 1-adrenergic blockade in subjects with essential hypertension is associated with, and probably explained by, inhibition of alpha 1-mediated, noradrenergic-dependent vasoconstriction. alpha 1-Adrenergic receptor antagonism did not modify body sodium concentration, the adrenomedullary component of the sympathetic nervous system, angiotensin II levels, or beta-adrenergic dependent mechanisms.
No takes yet. Share an insight, caveat, or question.
Beretta-Piccoli et al. (1986) studied mild to moderate essential hypertension (n=17). terazosin vs. placebo was evaluated on supine arterial pressure (p=<0.025). Terazosin treatment for 8 weeks reduced supine and upright arterial pressure and blunted cardiovascular pressor responsiveness to norepinephrine.
Synapse has enriched 10 related papers. Consider them for comparative context: